This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second View: Examining the potential of Arcellx’s CART-ddBCMA (anito-cel) with a focus on the Phase 1 Expansion Trial in Patients with Relapsed/Refractory Multiple Myeloma
Ticker(s): ACLXWho's the expert?
Institution: Medical College of Wisconsin
- Associate Professor (Oncology) at the Medical College of Wisconsin Scientific Director of the Plasma Cell Disorders and Adult Solid Tumors working committee in the Center for International Blood and Marrow Transplant Research (CIBMTR).
- Manages hundreds of patients with multiple myeloma
- Research interest in plasma cell cancers) and the use of hematopoietic cell transplantation to treat these diseases; Principal Investigator on numerous clinical trials in amyloidosis and multiple myeloma.
Interview GoalThis conversation will focus on novel therapies in development for multiple myeloma with a focus on the results presented at ASH 2023 from the Phase 1 Study of Arcellx's Anito-cel for the treatment of patients with relapsed or refractory multiple myeloma.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
